DayTwo’s Solution for Obesity Delivers Sustained Weight Loss, BMI Reduction, and a Cost-Effective Alternative to Expensive Medications

Food as medicine approach provides precise dietary recommendations to enable weight loss without the use of prescription medications

WALNUT CREEK, Calif.–(BUSINESS WIRE)–#DayTwoHealth–DayTwo, the leader in precision nutrition with the world’s largest and highest resolution microbiome discovery platform, offers an effective program that achieves sustained weight loss and reduction in Body Mass Index (BMI) for adults who are obese and for those with metabolic disease. This high tech, high touch solution equips members with precise nutrition recommendations using gut profiling, artificial intelligence, and clinical support to stabilize their blood sugar response to any food or food combination, based on their individual microbiome analysis. Unlike other programs, the DayTwo solution does not require an individual to remove any food groups, such as carbohydrates, from their diet. DayTwo is announcing these clinical outcomes in advance of World Microbiome Day on June 27.

DayTwo’s unique solution for metabolic disease has meaningful and sustained clinical outcomes for employers, health systems, and health plans enabling a path to remission. After one year, participants sustain remarkable results including an average of:

  • 19 lbs of weight loss, and
  • 3.3 point drop in BMI.

Additionally,

  • 85% of participants lost more than 10 lbs, and
  • 54% of participants reduced or eliminated prescription medications.

DayTwo’s precision nutrition solution is offered at a critical time, as rates of obesity continue to skyrocket in the U.S. The most recent Centers for Disease Control and Prevention (CDC) data estimates that 42% of adult Americans are obese.1 Common comorbidities for obesity include heart disease, stroke, diabetes, and increased risk for certain types of cancer.

Recent solutions for obesity are focused on the use of medications. Wegovy (also known as Semaglitude), an FDA approved drug, is estimated to cost $1,300 per month, making it and other prescription medications like it inaccessible to many patients due to cost. For those patients with certain coexisting metabolic conditions like diabetes, cost can be even more of a barrier. The price of insulin has risen sharply (an estimated increase of 43 times the rate of inflation), and the paired costs are often prohibitive.2

DayTwo’s food as medicine solution is a proven revolutionary approach for its 75,000 members. DayTwo’s protocol is based on scientific discoveries that people respond differently to the same food. Using microbiome profiling and a unique artificial intelligence-based algorithm, blood sugar response to food and food combinations can be accurately predicted. This is a completely different approach from traditional population health programs, which typically focus on monitoring, one-size-fits-all, or carb elimination diets.

“Our food as medicine approach is how we will turn the tide on obesity and metabolic disease in this country. Our sustained weight loss and BMI reduction results show that we are helping employees reach a healthy weight and get off expensive medications,” said Josh Stevens, president of DayTwo. “By offering an effective alternative to medications and leveraging the predictive power of an individual’s gut microbiome, we are seeing the life changing and life saving results of precision nutrition. In addition, our science allows participants to continue eating foods that are part of their lives and cultures. Employers, health systems, and health plans can now offer a proven path to remission of chronic conditions to their employees, patients, and members.”

Read more about the impact of metabolic disease in the U.S. here.

About DayTwo

DayTwo, the leader in precision nutrition with the world’s largest and highest resolution microbiome discovery platform, offers a sustainable path to remission for metabolic disease (diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease). Metabolic disease is the first condition to be addressed by DayTwo’s microbiome discovery platform.

The company’s solution includes gut microbiome profiling, artificial intelligence to predict blood sugar response to foods, and dedicated virtual care. The company’s results set a new national benchmark for diabetes and metabolic disease care — with significant sustained clinical results in reducing A1C, improving Time in Range, and reducing or eliminating prescription medications. DayTwo’s scientific research is cited by the National Institutes of Health as a foundational element in its 10 year, $150 million strategic plan for precision nutrition.

To learn more about DayTwo and its solutions for chronic disease, visit www.daytwo.com.

1 https://www.cdc.gov/obesity/data/adult.html
2 https://time.com/5709241/open-insulin-project/

Contacts

Lauren Kannry
lkannry@thorpesearl.com